Filtered By:
Cancer: Adenocarcinoma

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 766 results found since Jan 2013.

Cell-penetrating peptide-siRNA conjugate loaded YSA-modified nanobubbles for ultrasound triggered siRNA delivery.
In conclusion, the application of CPP-siRNA/YSA-NB with ultrasound may provide a strategy for the selective and efficient delivery of siRNA. PMID: 26492155 [PubMed - as supplied by publisher]
Source: Colloids and Surfaces - October 19, 2015 Category: Biotechnology Authors: Xie X, Yang Y, Lin W, Liu H, Liu H, Yang Y, Chen Y, Fu X, Deng J Tags: Colloids Surf B Biointerfaces Source Type: research

Antibody-mediated delivery of anti-KRAS-siRNA in vivo overcomes therapy resistance in colon cancer.
Conclusions:The coupling of siRNA against KRAS to anti-EGFR antibodies provides a novel therapy approach for KRAS-mutated EGFR-positive cancer cells in vitro and in vivo. These findings provide an innovative approach for cancer specific siRNA application and for enhanced therapeutic potential of monoclonal antibody therapy and personalized treatment of cancer entities. PMID: 25589625 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - January 14, 2015 Category: Cancer & Oncology Authors: Baeumer S, Baeumer N, Appel N, Terheyden L, Fremerey J, Schelhaas S, Wardelmann E, Buchholz F, Berdel WE, Müller-Tidow C Tags: Clin Cancer Res Source Type: research

086 * A NEW STRATEGY IN THE TREATMENT OF CHEMORESISTANT LUNG ADENOCARCINOMA VIA siRNA SPECIFIC SILENCING OF SRF, E2F1, SURVIVIN, HIF AND STAT 3
Conclusions: Our study proposed a new alternative in the treatment of chemoresistant NSCLC. Via siRNA specific silencing complex an accurate suppression of various chemoresistant cell lines can be achieved. Therefore, siRNA might represent an effective transient individualized regimen in the treatment of NSCLC as well an important platform for new chemotherapeutics.
Source: Interactive CardioVascular and Thoracic Surgery - September 18, 2013 Category: Cardiovascular & Thoracic Surgery Authors: Stoleriu, M. G., Steger, V., Mustafi, M., Schneider, W., Wendel, H. P., Walker, T., Schlensak, C. Tags: Thoracic experimental Source Type: research

Precision delivery of RAS-inhibiting siRNA to KRAS driven cancer via peptide-based nanoparticles.
Authors: Strand MS, Krasnick BA, Pan H, Zhang X, Bi Y, Brooks C, Wetzel C, Sankpal N, Fleming T, Goedegebuure SP, DeNardo DG, Gillanders WE, Hawkins WG, Wickline SA, Fields RC Abstract Over 95% of pancreatic adenocarcinomas (PDACs), as well as a large fraction of other tumor types, such as colorectal adenocarcinoma, are driven by KRAS activation. However, no direct RAS inhibitors exist for cancer therapy. Furthermore, the delivery of therapeutic agents of any kind to PDAC in particular has been hindered by the extensive desmoplasia and resultant drug delivery challenges that accompanies these tumors. Small interfer...
Source: Oncotarget - August 17, 2019 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Abstract 3903: A sub-set of DCLK1+ve colon cancer stem cells (CSCs) survive curcumin induced autophagy, while co-treatment with curcumin +DCLK1-siRNA eliminates CSCs: Role of long and short isofoms of DCLK1
Conclusion. Our studies strongly suggest that, 1) DCLK1 represents a functional protein for colon cancers, 2) combination of curcumin+DCLK1-siRNA may target and eradicate colon cancer stem cells., and 3) identifying small molecules that inhibit expression of S-isoform may allow to specifically target cancer stem cells, while sparing normal stem cells for cancer treatment purposes. This work was supported by NIH Granst to PS (R01CA09795909 and RO1CA0975909-S1). Citation Format: Shubhashish Sarkar, Malaney O'Connell, Carla, Kantara, Pomila Singh. A sub-set of DCLK1+ve colon cancer stem cells (CSCs) survive curcumin induced a...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Sarkar, S., O'Connell, M., Kantara, C., Singh, P. Tags: Tumor Biology Source Type: research

A new strategy in the treatment of chemoresistant lung adenocarcinoma via specific siRNA transfection of SRF, E2F1, Survivin, HIF and STAT3 BASIC SCIENCE
CONCLUSIONS In our study, we emphasized that siRNA interference might represent a productive platform for further research in order to investigate whether a new regimen in the treatment of multiresistant non-small-cell lung cancer could be established in vivo in the context of a multimodal cancer therapy.
Source: European Journal of Cardio-Thoracic Surgery - October 10, 2014 Category: Cardiovascular & Thoracic Surgery Authors: Stoleriu, M. G., Steger, V., Mustafi, M., Michaelis, M., Cinatl, J., Schneider, W., Nolte, A., Kurz, J., Wendel, H. P., Schlensak, C., Walker, T. Tags: Lung - cancer, Lung - transplantation, Mediastinum, Pleura, Cardiac - pharmacology, Lung - basic science Source Type: research

In Vivo KRAS Silencing with siRNA
This study highlights the potential translational impact of therapeutic RNA interference, which may have broad applications in oncology, especially for traditional "undruggable" targets. Mol Cancer Ther; 13(12); 2876–85. ©2014 AACR.
Source: Molecular Cancer Therapeutics - December 4, 2014 Category: Cancer & Oncology Authors: Pecot, C. V., Wu, S. Y., Bellister, S., Filant, J., Rupaimoole, R., Hisamatsu, T., Bhattacharya, R., Maharaj, A., Azam, S., Rodriguez-Aguayo, C., Nagaraja, A. S., Morelli, M. P., Gharpure, K. M., Waugh, T. A., Gonzalez-Villasana, V., Zand, B., Dalton, H. Tags: Small Molecule Therapeutics Source Type: research

siRNA-induced TRAF6 knockdown promotes the apoptosis and inhibits the invasion of human lung cancer SPC-A1 cells.
Authors: He Z, Huang C, Lin G, Ye Y Abstract Tumor necrosis factor receptor-associated factor 6 (TRAF6) has been found to be involved in multiple cancers. However, the effect of small interfering RNA (siRNA)‑induced knockdown of TRAF6 on the biological behaviors of cancer cells remains unknown. Thus, the present study aimed to investigate the effect of siRNA-induced knockdown of TRAF6 on the biological behaviors of human lung cancer SPC-A1 cells. The expression of TRAF6 was determined in human lung adenocarcinoma A549, non-small cell lung cancer H1650, human airway epithelial Calu-3 and human lung cancer SPC-A1 ...
Source: Oncology Reports - February 9, 2016 Category: Cancer & Oncology Tags: Oncol Rep Source Type: research

Methotrexate induced cell death mechanisms in MCF-7 adenocarcinoma breast cancer cells: Enhanced cytotoxicity following dff45-siRNA pre-treatment
Publication date: Available online 30 August 2018Source: SynergyAuthor(s): Fatemeh Kiani, Negin Rasouli, Tahereh Kashkoolinejad, Shahrokh Safarian, Seyed Jalal Zargar, Nader SheibaniAbstractThere are many efforts to diminish risks associated with the use of cancer chemotherapeutic agents through design and utilization of new strategies including gene therapy. We previously showed knockdown of dff45 or overexpression of dff40, the important apoptosis regulators, resulted in enhanced sensitization of cancer cells to chemotherapeutic agents. Here we show that pre-treatment with dff45-siRNA additively increased the overall cyt...
Source: Synergy - August 31, 2018 Category: Molecular Biology Source Type: research

Targeting KRAS Mutant Lung Cancer Cells with siRNA-Loaded Bovine Serum Albumin Nanoparticles
ConclusionsBSA nanoparticles loaded with mutant specific siRNA are a promising therapeutic approach for KRAS-mutant cancers.
Source: Pharmaceutical Research - July 8, 2019 Category: Drugs & Pharmacology Source Type: research

Therapeutic effects of bach1 siRNA on human breast adenocarcinoma cell line.
CONCLUSION: Our results suggest that the bach1 can be considered as a potent adjuvant in breast cancer therapy. PMID: 28092843 [PubMed - as supplied by publisher]
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - January 12, 2017 Category: Drugs & Pharmacology Authors: Aletaha M, Mansoori B, Mohammadi A, Fazeli M, Baradaran B Tags: Biomed Pharmacother Source Type: research

ProNGF siRNA inhibits cell proliferation and invasion of pancreatic cancer cells and promotes anoikis
ConclusionProNGF expression is elevated in PDAC tissues and cell lines, and proNGF siRNA can inhibit cell proliferation, migration, and invasion, and promote anoikis of pancreatic cancer cells, in which decreased proNGF may participate.
Source: Biomedicine and Pharmacotherapy - January 11, 2019 Category: Drugs & Pharmacology Source Type: research

Spray drying siRNA-lipid nanoparticles for dry powder pulmonary delivery
This study verifies the successful spray drying procedure of LNP-siRNA systems maintaining their integrity and mediating strong gene silencing efficiency on mRNA and protein levels both in vitro and ex vivo. The successful spray drying procedure of LNP-siRNA formulations in 5% lactose solution creates a novel siRNA-based therapy option to target respiratory diseases such as lung cancer, asthma, COPD, cystic fibrosis and viral infections.PMID:36126785 | DOI:10.1016/j.jconrel.2022.09.021
Source: Cancer Control - September 20, 2022 Category: Cancer & Oncology Authors: Christoph M Zimmermann Domizia Baldassi Karen Chan Nathan B P Adams Alina Neumann Diana Leidy Porras-Gonzalez Xin Wei Nikolaus Kneidinger Mircea Gabriel Stoleriu Gerald Burgstaller Dominik Witzigmann Paola Luciani Olivia M Merkel Source Type: research

Cancers, Vol. 15, Pages 2901: Extracellular Vesicles Derived from Human Umbilical Cord Mesenchymal Stromal Cells as an Efficient Nanocarrier to Deliver siRNA or Drug to Pancreatic Cancer Cells
In conclusion, the use of UC-MSC-derived EVs as a drug delivery system for siRNAs or drugs could be a promising approach for the targeted treatment of PDAC.
Source: Cancers - May 24, 2023 Category: Cancer & Oncology Authors: Florian Draguet Nathan Dubois Cyril Bouland Karlien Pieters Dominique Bron Nathalie Meuleman Basile Stamatopoulos Laurence Lagneaux Tags: Article Source Type: research

STAT6 siRNA Matrix-Loaded Gelatin Nanocarriers: Formulation, Characterization, and Ex Vivo Proof of Concept Using Adenocarcinoma Cells.
Abstract The clinical utility of siRNA therapy has been hampered due to poor cell penetration, nonspecific effects, rapid degradation, and short half-life. We herewith proposed the formulation development of STAT6 siRNA (S6S) nanotherapeutic agent by encapsulating them within gelatin nanocarriers (GNC). The prepared nanoformulation was characterized for size, charge, loading efficiency, release kinetics, stability, cytotoxicity, and gene silencing assay. The stability of S6S-GNC was also assessed under conditions of varying pH, serum level, and using electrophoretic assays. In vitro cytotoxicity performance was ev...
Source: Biomed Res - November 7, 2013 Category: Research Authors: Youngren SR, Tekade RK, Gustilo B, Hoffmann PR, Chougule MB Tags: Biomed Res Int Source Type: research